Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11291 |
FKBP12 PROTAC dTAG-13
dTAG-13 |
Epigenetic Reader Domain | Chromatin/Epigenetic |
FKBP12 PROTAC dTAG-13 (dTAG-13) is a degrader of FKBP12F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 (dTAG-13) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN. FKBP12 PROTAC dTAG-13 (dTAG-13) is a PROTAC-based heterobifunctional degrader. | |||
T36252 | dTAG-13-NEG | ||
Negative control for dTAG-13. | |||
T40031 |
Thalidomide-O-C6-NH2 hydrochloride
4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride,萨力多胺-O-C6-氨基盐酸盐 |
E3 Ligase Ligand-Linker Conjugate | PROTAC |
Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) 是一种合成的E3 连接酶配体 -linker 偶联物,用于 PROTAC dTAG-13 的合成。其中 dTAG-13 是一种 FKBP12F36V 和 BET 的降解剂。 | |||
T18824 | Thalidomide-O-C6-NH2 TFA | Others | Others |
Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1]. | |||
T18825 |
Thalidomide-O-C6-NH2
|
Others | Others |
Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1]. |